These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 687671)
21. Enhanced cytotoxic interaction between 5-fluorouracil and 4-hydroperoxycyclophosphamide against L1210 murine leukemic cells: applicability to ex vivo purging. Mao XY; Higashigawa M; M'Soka T; Shimono Y; Nagata T; Inamochi H; Cao DC; Hori H; Kawasaki H; Sakurai M Cancer Invest; 1999; 17(7):486-93. PubMed ID: 10518193 [TBL] [Abstract][Full Text] [Related]
22. Immunological concepts and the combination of cyclophosphamide with 5-aza-2'-deoxycytidine on L1210 in vivo. Zaharko DS J Immunopharmacol; 1985; 7(2):195-202. PubMed ID: 2411821 [TBL] [Abstract][Full Text] [Related]
23. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia. Avery TL; Roberts D Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368 [TBL] [Abstract][Full Text] [Related]
24. The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents. Woodman RJ; Sirica AE; Gang M; Kline I; Venditti JM Chemotherapy; 1973; 18(3):169-83. PubMed ID: 4119363 [No Abstract] [Full Text] [Related]
25. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210. Góra-Tybor J; Robak T; Warzocha K; Grieb P Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633 [TBL] [Abstract][Full Text] [Related]
26. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice. Fujimoto S Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525 [TBL] [Abstract][Full Text] [Related]
27. Influence of some sulfhydryl compounds on the antineoplastic effectiveness of 5-fluorouracil and 6-mercaptopurine. Danysz A; Wierzba K; Wutkiewicz M; Pniewska A; Pragłowski T; Burba-Anczewska I Arch Immunol Ther Exp (Warsz); 1984; 32(3):345-9. PubMed ID: 6395826 [TBL] [Abstract][Full Text] [Related]
28. Enhancement of antileukemic effect in combination of 5-fluorouracil and OK-432. Koshimura S; Ryoyama K Cancer Treat Rep; 1977; 61(1):17-27. PubMed ID: 324619 [TBL] [Abstract][Full Text] [Related]
29. In vivo DNA cross-linking by cyclophosphamide: comparison of human chronic lymphatic leukemia cells with mouse L1210 leukemia and normal bone marrow cells. DeNeve W; Valeriote F; Edelstein M; Everett C; Bischoff M Cancer Res; 1989 Jul; 49(13):3452-6. PubMed ID: 2731167 [TBL] [Abstract][Full Text] [Related]
30. Combined therapy of L1210 leukemia with Damvar and cytostatics. Pujman V; Cernochová S Neoplasma; 1979; 26(5):521-3. PubMed ID: 522924 [TBL] [Abstract][Full Text] [Related]
31. Effect of pyrimidines, purines and their nucleosides on antitumor activity of 5-fluorouracil against L-1210 leukemia. Iigo M; Ando N; Hoshi A; Kuretani K J Pharmacobiodyn; 1982 Jul; 5(7):515-20. PubMed ID: 7131236 [TBL] [Abstract][Full Text] [Related]
32. Synergistic effects of Actinobacillus suis cells in combination with 5-fluorouracil on mice bearing murine L1210 leukemia cells. Watanabe T; Itoh S Cancer Immunol Immunother; 1997 Jun; 44(4):216-20. PubMed ID: 9222280 [TBL] [Abstract][Full Text] [Related]
33. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice. Warzocha K; Robak T Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue. Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402 [TBL] [Abstract][Full Text] [Related]
35. Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia. Tobias JS; Parker LM; Tattersall MH; Frei E Br J Cancer; 1975 Aug; 32(2):199-207. PubMed ID: 1212350 [TBL] [Abstract][Full Text] [Related]
36. Timing- and sequence-dependent synergism between etoposide and methotrexate or etoposide, methotrexate and 5-fluorouracil in advanced leukemia L1210. Osswald H; Herrmann R; Youssef M Cancer Lett; 1985 Dec; 29(3):277-82. PubMed ID: 4075296 [TBL] [Abstract][Full Text] [Related]
37. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation. Hoeschele JD; Showalter HD; Kraker AJ; Elliott WL; Roberts BJ; Kampf JW J Med Chem; 1994 Aug; 37(17):2630-6. PubMed ID: 8064793 [TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of pyrimidinones, a class of small-molecule biological response modifiers. Li LH; Wallace TL; Wierenga W; Skulnick HI; DeKoning TF J Biol Response Mod; 1987 Feb; 6(1):44-55. PubMed ID: 3559628 [TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia. Dombernowsky P; Nissen NI Eur J Cancer (1965); 1976 Mar; 12(3):181-8. PubMed ID: 939236 [No Abstract] [Full Text] [Related]
40. 5-Fluorouracil and derivatives in cancer chemotherapy. 3. In vivo enhancement of antitumor activity of 5-fluorouracil (FU) and 5-fluoro-2'-deoxyuridine (FUDR). Jato J; Windheuser JJ J Pharm Sci; 1973 Dec; 62(12):1975-8. PubMed ID: 4271579 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]